133
Participants
Start Date
April 12, 2021
Primary Completion Date
June 6, 2022
Study Completion Date
August 9, 2022
ATR-002
150mg tablets for oral intake
Placebo
matching tablets for oral intake
Atriva study site 49006, Augsburg
Atriva study site 49001, Berlin
Atriva study site 49013, Berlin
Atriva study site 49011, Dresden
Atriva study site 49003, Frankfurt
Atriva study site 49008, Frankfurt
Atriva study site 49009, Freiburg im Breisgau
Atriva study site 49007, Halle
Atriva study site 49004, Münster
Atriva study site 49012, Rostock
Atriva study site 91002, Ahmedabad
Atriva study site 91001, Aligarh
Atriva study site 91011, Aurangabad
Atriva study site 91008, Mumbai
Atriva study site 91009, Mumbai
Atriva study site 91003, New Delhi
Atriva study site 91004, Raipur
Atriva study site 31001, Eindhoven
Atriva study site 31002, Tilburg
Atriva study site 48002, Bolesławiec
Atriva study site 48004, Bolesławiec
Atriva study site 48003, Warsaw
Atriva study site 40006, Bucharest
Atriva study site 40002, Iași
Atriva study site 40004, Sibiu
Atriva study site 40008, Suceava
Atriva study site 40003, Timișoara
Atriva study site 27005, Benoni
Atriva study site 27002, Cape Town
Atriva study site 27003, George
Atriva study site 27006, KwaZulu
Atriva study site 27007, Mayville
Atriva study site 27008, Pretoria
Atriva study site 34001, Barcelona
Atriva study site 34011, Lleida
Atriva study site 34002, Madrid
Atriva study site 34005, Madrid
Atriva study site 34008, Madrid
Atriva study site 34010, Pontevedra
Atriva study site 34004, Valencia
Lead Sponsor
Atriva Therapeutics GmbH
INDUSTRY